Cartesian Therapeutics, Inc. RNAC
Cartesian Therapeutics, Inc. (Nasdaq: RNAC) is an immunology/inflammation drug developer. Its lead program, Descartes-08, is in Phase 3 for myasthenia gravis (MG).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Descartes-08 | myasthenia gravis (MG) | cell therapy | Phase 3 |
| Descartes-08 | myositis/dermatomyositis | cell therapy | Phase 2 |
Recent results and decisions
- Sep 29, 2026positive Retreatment of 5 MG patients gave mean MG-ADL reduction of 6.6 points at Month 12; no new safety signals, no CRS or ICANS.
Retreated patients observed an average MG-ADL reduction of 6.6 (±4.2) points from baseline at Month 12.
Filing - positive Retreatment data for Descartes-08 in MG showed deep and durable responses, with a mean 6.6-point MG-ADL reduction from baseline at Month 12.
At Month 12 following retreatment, patients achieved a mean MG-ADL reduction of 6.6 (±4.2) points from baseline.
Filing - Apr 30, 2026started Phase 2 TRITON trial of Descartes-08 in myositis initiated.
Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
- Sanofi SNY
- Argenx SE ARGX
- Roivant Sciences Ltd. ROIV
- Immunovant, Inc. IMVT
- Celldex Therapeutics, Inc. CLDX
- Biohaven Ltd. BHVN
- BioCryst Pharmaceuticals, Inc. BCRX
- Zenas BioPharma ZBIO
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.